Literature DB >> 19069636

Bone marrow cell transplant does not prevent or reverse murine liver cirrhosis.

L F Quintanilha1, E G Mannheimer, A B Carvalho, B D Paredes, J V Dias, A S Almeida, B Gutfilen, L M Barbosa da Fonseca, C M C Resende, G F M Rezende, A C Campos de Carvalho, R C S Goldenberg.   

Abstract

We tested the effect of bone marrow cell (BMC) transplantation in either preventing or reversing cirrhosis on an experimental model of chronic liver disease. Female Wistar rats were fed a liquid alcohol diet and received intraperitoneal injections of carbon tetrachloride (CCl4) over 15 weeks. Ten animals (cell-treated group) received five injections of BMCs during the cirrhosis induction protocol (on the 4th, 6th, 8th, 10th, and 12th weeks) and four animals received the cells after liver injury was established through tail vein. Nine animals (nontreated group) were submitted to the previously described protocols; however, they received vehicle injections. Analyses were performed to verify whether the infusion of cells was effective in preventing the development of cirrhosis in our model of induction, and if the cells could reverse cirrhosis once it was established. Hepatic architecture and fibrotic septa were analyzed in liver slices stained with hematoxilin & eosin and Sirius red, respectively. Fibrosis quantification was measured by Sirius red histomorphometry. Indirect immunofluorescence was performed to detect the amount of tissue transglutaminase 2. Blood analyses were performed to assess liver injury and function by the assessment of alanine aminotransferase and albumin. Ultrasound was performed to analyze the portal vein caliber and presence of ascitis. Cirrhosis features (regenerative nodules and fibrous septa) were observed in histopathology after 15 weeks of continuous hepatic injury in nontreated and cell-treated groups. Collagen content, immunofluorescence analysis, and biochemical and ultrasound parameters were similar in nontreated and cell-treated groups; however, both groups showed significant differences compared to a normal control group. Cell infusions with bone marrow-derived cells seem to be ineffective in improving morphofunctional parameters of the liver when applied to chronic cases either during or after establishment of the hepatic lesion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19069636     DOI: 10.3727/096368908786576453

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  12 in total

1.  Bone marrow progenitor cells do not contribute to liver fibrogenic cells.

Authors:  Bruno Diaz Paredes; Lanuza Alaby Pinheiro Faccioli; Luiz Fernando Quintanilha; Karina Dutra Asensi; Camila Zaverucha do Valle; Paulo César Canary; Christina Maeda Takiya; Antonio Carlos Campos de Carvalho; Regina Coeli Dos Santos Goldenberg
Journal:  World J Hepatol       Date:  2012-10-27

2.  Cell Therapy Using Adipose-Derived Stem Cells for Chronic Liver Injury in Mice.

Authors:  Kazuo Ohashi; Yoshinori Matsubara; Kohei Tatsumi; Ayako Kohori; Rie Utoh; Hiroshi Kakidachi; Akihiro Horii; Masahiro Tsutsumi; Teruo Okano
Journal:  Cell Med       Date:  2012-05-14

3.  Liver scaffolds obtained by decellularization: A transplant perspective in liver bioengineering.

Authors:  Marlon Lemos Dias; Bruno Andrade Paranhos; Regina Coeli Dos Santos Goldenberg
Journal:  J Tissue Eng       Date:  2022-06-20       Impact factor: 7.940

4.  Ultrasound imaging in an experimental model of fatty liver disease and cirrhosis in rats.

Authors:  Andréia S Lessa; Bruno D Paredes; Juliana V Dias; Adriana B Carvalho; Luiz Fernando Quintanilha; Christina M Takiya; Bernardo R Tura; Guilherme F M Rezende; Antonio C Campos de Carvalho; Célia M C Resende; Regina C S Goldenberg
Journal:  BMC Vet Res       Date:  2010-01-29       Impact factor: 2.741

Review 5.  Stem cell researches in Brazil: present and future challenges.

Authors:  Mayana Zatz
Journal:  Stem Cell Rev Rep       Date:  2009-02-19       Impact factor: 5.739

Review 6.  Antifibrosis: to reverse the irreversible.

Authors:  Ziv Paz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

7.  REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial.

Authors:  A King; D Barton; H A Beard; N Than; J Moore; C Corbett; J Thomas; K Guo; I Guha; D Hollyman; D Stocken; C Yap; R Fox; S J Forbes; P N Newsome
Journal:  BMJ Open       Date:  2015-03-20       Impact factor: 2.692

8.  Bone marrow mesenchymal cells improve muscle function in a skeletal muscle re-injury model.

Authors:  Bruno M Andrade; Marcelo R Baldanza; Karla C Ribeiro; Anderson Porto; Ramon Peçanha; Fabio S A Fortes; Gisele Zapata-Sudo; Antonio C Campos-de-Carvalho; Regina C S Goldenberg; João Pedro Werneck-de-Castro
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

9.  99m-Technetium binding site in bone marrow mononuclear cells.

Authors:  Grazielle Dias Suhett; Sergio Augusto Lopes de Souza; Adriana Bastos Carvalho; Rachel de Pinho Rachid; Narcisa Leal da Cunha-E-Silva; Antonio Carlos Campos de Carvalho; Lea Mirian Barbosa da Fonseca; Regina Coeli dos Santos Goldenberg; Bianca Gutfilen
Journal:  Stem Cell Res Ther       Date:  2015-06-04       Impact factor: 6.832

10.  Proceedings of the signature series event of the international society for cellular therapy: "Advancements in cellular therapies and regenerative medicine in digestive diseases," London, United Kingdom, May 3, 2017.

Authors:  Rachele Ciccocioppo; Claudia C Dos Santos; Daniel C Baumgart; Giuseppina C Cangemi; Vincenzo Cardinale; Carolina Ciacci; Paolo De Coppi; Debashis Haldar; Catherine Klersy; M Cristina Nostro; Michael Ott; Lorenzo Piemonti; Alice A Tomei; Basak Uygun; Stefania Vetrano; Giuseppe Orlando
Journal:  Cytotherapy       Date:  2018-02-15       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.